ASCO recommends osimertinib consolidation for patients with unresectable, stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation who have completed chemoradiation.
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...